The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2025 | Determining optimal treatment sequencing & timing of surgery in resectable gastroesophageal cancers
Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, shares how optimal gastroesophageal cancer treatment begins with comprehensive multidisciplinary staging and planning. Dr Janjigian highlights the shift away from radiation therapy toward systemic approaches, noting that patients die from metastatic disease, not local recurrence. The MATTERHORN study (NCT04592913) demonstrates the importance of perioperative systemic therapy. Key recommendations include thorough staging with laparoscopy when indicated, and considering longer duration perioperative therapy for advanced disease to better understand tumor biology and potentially cure more patients. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2025 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
